We raise the possibility that the combination of methamphetamine use and HIV represents a ‘perfect storm’ for the COVID-19 pandemic in men who have sex with men,” said Dr. Carrico, associate professor and lead author on the AIDS and Behavior editorial, “Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.”
In a process referred to as residual immune dysregulation, HIV damages the immune system, even when people are taking medicine to reduce the viral load. Methamphetamine further damages the immune system, which could increase the risk for COVID-19, according to those studying these vulnerable populations.
For the editorial, Dr. Carrico collaborated with a group of experts from San Diego State University’s Department of Psychology, CUNY Graduate School of Public Health and Health Policy, Northwestern University’s Feinberg School of Medicine, and SUNY Downstate Health Sciences University.
The authors provide an overview of biological and behavioral risks and how methamphetamine use and HIV impact COVID-19 risk and fuel community-level transmission.
Among those risks, the authors cited:
“These risks emphasize the urgent need for further research to halt the COVID-19 spread and to further protect at-risk populations like those with co-occurring meth use and HIV,” Dr. Carrico said.
He points to recent clusters of COVID-19 infections that were reportedly associated with a Miami circuit party in March 2020.
“The infections stress the need for research that will examine substance use and other behavioral correlates of adherence to social distancing guidelines,” he said.
In the editorial, the authors suggest the use of mobile devices, such as smartphones or tablets, to provide support to those with mental health and substance use disorders while promoting greater adherence to social distancing adherence in people living with HIV who use stimulants.
Dr. Carrico is currently leading a randomized controlled trial funded by the National Institute on Drug Abuse to test the efficacy of a mHealth intervention for this population in collaboration with Keith Horvath, Ph.D., San Diego State University, and Sabina Hirshfield, Ph.D., SUNY Downstate Health Sciences University, who serve as multiple principal investigators.
This trial builds upon Dr. Carrico’s prior research demonstrating the efficacy of a behavioral intervention for achieving durable clinically meaningful reductions in HIV viral load with this population.
Copyright: 2024 University of Miami. All Rights Reserved.
Emergency Information
Privacy Statement & Legal Notices
Individuals with disabilities who experience any technology-based barriers accessing University websites can submit details to our online form.